Longeveron Inc. (“Longeveron”) is a leading clinical stage biotechnology company developing cell therapies for chronic aging-related diseases and other life-threatening conditions, for which there are no approved treatments. With its Initial Public Offering, the management is in a comfortable position to complete the current ongoing trials and to initiate around four additional Phase 2 clinical trials, which may subsequently lead to commercialization and a huge spike in revenues. During the firs ....
